These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 21768798)

  • 1. Persistent hiccups associated with switching from risperidone to aripiprazole in a schizophrenic patient with cerebral palsy.
    Yeh YW
    Clin Neuropharmacol; 2011; 34(4):135-6. PubMed ID: 21768798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hiccups associated with switching from olanzapine to aripiprazole in a patient with paranoid schizophrenia.
    Hori H; Nakamura J
    Clin Neuropharmacol; 2014; 37(3):88-9. PubMed ID: 24824665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
    Gründer G; Kungel M; Ebrecht M; Göröcs T; Modell S
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S21-5. PubMed ID: 16508892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aripiprazole-associated hiccups: a case and closer look at the association between hiccups and antipsychotics.
    Silverman MA; Leung JG; Schak KM
    J Pharm Pract; 2014 Dec; 27(6):587-90. PubMed ID: 25107419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aripiprazole as a dopamine partial agonist: positive and negative effects.
    Glick ID; Duggal V; Hodulik C
    J Clin Psychopharmacol; 2006 Feb; 26(1):101-3. PubMed ID: 16415723
    [No Abstract]   [Full Text] [Related]  

  • 6. Aripiprazole in children and adolescents with conduct disorder: a single-center, open-label study.
    Ercan ES; Uysal T; Ercan E; Akyol Ardic U
    Pharmacopsychiatry; 2012 Jan; 45(1):13-9. PubMed ID: 21993869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aripiprazole in the treatment of Alzheimer's disease.
    De Deyn PP; Drenth AF; Kremer BP; Oude Voshaar RC; Van Dam D
    Expert Opin Pharmacother; 2013 Mar; 14(4):459-74. PubMed ID: 23350964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia.
    Kim SW; Shin IS; Kim JM; Youn T; Yang SJ; Hwang MY; Yoon JS
    Clin Neuropharmacol; 2009; 32(4):224-6. PubMed ID: 19644229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists].
    Costentin J
    Ann Pharm Fr; 2009 Sep; 67(5):310-9. PubMed ID: 19695367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of action of brexpiprazole: comparison with aripiprazole.
    Stahl SM
    CNS Spectr; 2016 Feb; 21(1):1-6. PubMed ID: 26899451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.
    Keck PE; McElroy SL
    Expert Opin Investig Drugs; 2003 Apr; 12(4):655-62. PubMed ID: 12665420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aripiprazole-induced hiccups: a case report.
    Ray P; Zia Ul Haq M; Nizamie SH
    Gen Hosp Psychiatry; 2009; 31(4):382-4. PubMed ID: 19555801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do dopamine partial agonists have partial efficacy as antipsychotics?
    Stahl SM
    CNS Spectr; 2008 Apr; 13(4):279-82. PubMed ID: 18408646
    [No Abstract]   [Full Text] [Related]  

  • 15. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML; Shen WW; Chen CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aripiprazole induced Parkinsonism: A case report].
    Pasquier de Franclieu S; Germain C; Petitjean F
    Encephale; 2009 Oct; 35(5):496-8. PubMed ID: 19853725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
    Tadori Y; Kikuchi T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A new pharmacological strategy for schizophrenia: the partial agonists of D2 dopaminergic receptors. The principle characteristics of aripiprazole].
    Costentin J
    Encephale; 2009 Feb; 35(1):66-72. PubMed ID: 19250996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aripiprazole's receptor pharmacology and extrapyramidal side effects.
    Poyurovsky M; Weizman R; Weizman A
    Am J Psychiatry; 2008 Mar; 165(3):398; author reply 398-9. PubMed ID: 18316435
    [No Abstract]   [Full Text] [Related]  

  • 20. Combination loxapine and aripiprazole for refractory hallucinations in schizophrenia.
    Sokolski KN
    Ann Pharmacother; 2011 Jul; 45(7-8):e36. PubMed ID: 21672885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.